Bayesian ordered lattice design for Phase I clinical trials
Wang, G.-M.; Tatsuoka, C.
Show abstract
We develop a new framework specifically for early Phase I clinical trials called Bayesian Ordered Lattice Design (BOLD). This study is motivated by two key factors. First, Phase I clinical trials typically involve relatively small sample sizes, which can make the use of prior information on dose-limiting toxicity (DLT) rates highly significant. To address this challenge, the proposed Bayesian methodology incorporates prior information and posterior updating to guide dose selection, toxicity monitoring, early stopping and identification of the maximum tolerable dose (MTD). Second, a natural ordering among toxicity probabilities across different dose levels can be utilized, with the idea being that analysis of dose-level posterior probabilities can and should acquire insights from data obtained at other dose levels, by leveraging their order relationship. Our proposed approach employs straightforward dose-level Bayesian specifications and relies on intuitive and clinically interpretable DLT rate posterior probabilities for decision making. Importantly, we show that it can often outperform popular methods, in terms of accuracy in determining the MTD. This Bayesian approach is also computationally simple and avoids simulation.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Chemotherapy-Induced Cachexia and Model-Informed Dosing to Preserve Lean Mass in Cancer Treatment 92%
- Combination Treatment Optimization Using aPan-Cancer Pathway Model 92%
- A regularized functional regression model enabling transcriptome-wide dosage-dependent association study of cancer drug response 91%
Similar papers in this journal
Similar papers in this journal
- Cluster-Based Toxicity Estimation of Osteoradionecrosis via Unsupervised Machine Learning: Moving Beyond Single Dose-Parameter Normal Tissue Complication Probability by Using Whole Dose-Volume Histograms for Cohort Risk Stratification 92%
- Revisiting a null hypothesis: exploring the parameters of oligometastasis treatment 92%
- Bayesian Learning to Reduce Cardiac Risk for Locally Advanced NSCLC Patients Based on Personalized Radiotherapy Prescription 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.